Lixte Biotechnology Holdings, Inc. announced that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy. In Nature Communications (15 Dec 2021), lead author Yu-Ting Yen and colleagues at the China Medical University and Hospital, Taichung, Taiwan reported that treatment with LB-100 is associated with new antigen production, tumor infiltration of cytotoxic T cells, and enhanced responsiveness to immune checkpoint blockade in mouse models of colorectal, triple-negative breast, and pancreatic cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | -0.84% | +3.98% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 5.29M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+43.96% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors